Literature DB >> 11698224

The mucosal immune system: primary target for HIV infection and AIDS.

R S Veazey1, P A Marx, A A Lackner.   

Abstract

Despite intensive research, several questions remain regarding the pathogenesis of infection with HIV-1. Recently, it has been shown that simian immunodeficiency virus (SIV) selectively targets and destroys specific subsets of CD4+ T cells that are abundant in mucosal tissues but rare in peripheral lymphoid tissues. This finding could be highly relevant in explaining a major paradox in the infection and elimination of CD4+ T cells during HIV infection: the progressive decline in the number of CD4+ T cells in the blood, despite the paucity of HIV-infected cells in this tissue. This article discusses the hypothesis that infection with HIV and SIV, and the resulting disease, is governed by the state of cellular activation and the expression of chemokine receptors by specific subsets of CD4+ T cells residing in mucosal lymphoid tissues, rather than those found in the peripheral blood or lymph nodes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11698224     DOI: 10.1016/s1471-4906(01)02039-7

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  47 in total

1.  Highly uneven distribution of tenofovir-selected simian immunodeficiency virus in different anatomical sites of rhesus macaques.

Authors:  Magdalena Magierowska; Flavien Bernardin; Seema Garg; Silvija Staprans; Michael D Miller; Koen K A Van Rompay; Eric L Delwart
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

Review 2.  HIV-1 and the hijacking of dendritic cells: a tug of war.

Authors:  Marie Larsson
Journal:  Springer Semin Immunopathol       Date:  2005-01

3.  Virus-specific T cell responses in macaques acutely infected with SHIV(sf162p3).

Authors:  Bapi Pahar; Xiaolei Wang; Jason Dufour; Andrew A Lackner; Ronald S Veazey
Journal:  Virology       Date:  2007-02-16       Impact factor: 3.616

4.  R5 variants of human immunodeficiency virus type 1 preferentially infect CD62L- CD4+ T cells and are potentially resistant to nucleoside reverse transcriptase inhibitors.

Authors:  Françoise Gondois-Rey; Angelique Biancotto; Marcelo Antonio Fernandez; Lise Bettendroffer; Jana Blazkova; Katerina Trejbalova; Marjorie Pion; Ivan Hirsch
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

Review 5.  How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?

Authors:  Per Johan Klasse; Rogier W Sanders; Andrea Cerutti; John P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-20       Impact factor: 2.205

6.  Profound loss of intestinal Tregs in acutely SIV-infected neonatal macaques.

Authors:  Xiaolei Wang; Huanbin Xu; Chanjuan Shen; Xavier Alvarez; David Liu; Bapi Pahar; Marion S Ratterree; Lara A Doyle-Meyers; Andrew A Lackner; Ronald S Veazey
Journal:  J Leukoc Biol       Date:  2014-12-09       Impact factor: 4.962

Review 7.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

8.  Intestinal double-positive CD4+CD8+ T cells of neonatal rhesus macaques are proliferating, activated memory cells and primary targets for SIVMAC251 infection.

Authors:  Xiaolei Wang; Arpita Das; Andrew A Lackner; Ronald S Veazey; Bapi Pahar
Journal:  Blood       Date:  2008-09-26       Impact factor: 22.113

9.  Dynamics of viral replication in blood and lymphoid tissues during SIVmac251 infection of macaques.

Authors:  Abdelkrim Mannioui; Olivier Bourry; Pierre Sellier; Benoit Delache; Patricia Brochard; Thibault Andrieu; Bruno Vaslin; Ingrid Karlsson; Pierre Roques; Roger Le Grand
Journal:  Retrovirology       Date:  2009-11-23       Impact factor: 4.602

10.  Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection.

Authors:  Marc C Levesque; M Anthony Moody; Kwan-Ki Hwang; Dawn J Marshall; John F Whitesides; Joshua D Amos; Thaddeus C Gurley; Sallie Allgood; Benjamin B Haynes; Nathan A Vandergrift; Steven Plonk; Daniel C Parker; Myron S Cohen; Georgia D Tomaras; Paul A Goepfert; George M Shaw; Jörn E Schmitz; Joseph J Eron; Nicholas J Shaheen; Charles B Hicks; Hua-Xin Liao; Martin Markowitz; Garnett Kelsoe; David M Margolis; Barton F Haynes
Journal:  PLoS Med       Date:  2009-07-07       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.